Supernus (SUPN) CFO Timothy C. Dec Receives 1,250-Share Award

What Happened

• Timothy C. Dec, Senior Vice President & Chief Financial Officer of Supernus Pharmaceuticals (SUPN), was issued 1,250 shares on July 29, 2026 as an award/settlement of a prior performance-based grant. The shares were acquired at $0.00 (no cash paid) and reported as a derivative/award transaction on a Form 4.

Key Details

• Transaction date and price: 2026-07-29; 1,250 shares at $0.00 per share.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The shares stem from Performance Share Units awarded on Feb. 19, 2025; a portion vested after individual performance objectives (established May 3, 2025) were met.
• Filing timeliness: Reported on 2026-07-31 for a 2026-07-29 transaction — filed within the normal reporting window (not marked late).

Context

• This was an award/settlement of previously granted performance share units (a derivative compensation event), not an open-market buy or sell. Such grants are common executive compensation and do not directly indicate the insider’s intent to buy or sell stock.